iBio Inc IBIO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IBIO is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $2.22
- Day Range
- $2.20–2.27
- 52-Week Range
- $1.02–15.99
- Bid/Ask
- $2.15 / $2.26
- Market Cap
- $19.40 Mil
- Volume/Avg
- 23,207 / 143,404
Key Statistics
- Price/Earnings (Normalized)
- 0.03
- Price/Sales
- 85.50
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
iBio Inc is a part of the healthcare sector. Its main business is commercialized technologies and product candidates and manufacturing services to clients and collaborators. Its main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates. Its products are used to combat various areas such as fibrotic diseases, cancers, and infectious diseases. The company operates in two segments: Biopharmaceuticals and Bioprocessing activities, conducted within iBio, Inc. and CDMO segment, conducted within iBio CDMO.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 23
- Website
- https://www.ibioinc.com
Valuation
|
Metric
|
IBIO
|
|---|---|
Price/Earnings (Normalized) | 0.03 |
Price/Book Value | 0.77 |
Price/Sales | 85.50 |
Price/Cash Flow | — |
Price/Earnings
IBIO
Financial Strength
|
Metric
|
IBIO
|
|---|---|
Quick Ratio | 0.91 |
Current Ratio | 1.69 |
Interest Coverage | −133.26 |
Quick Ratio
IBIO
Profitability
|
Metric
|
IBIO
|
|---|---|
Return on Assets (Normalized) | −30.60% |
Return on Equity (Normalized) | −79.31% |
Return on Invested Capital (Normalized) | −38.54% |
Return on Assets
IBIO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Lmwdgfwbyg | Fztd | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Cksxqvyl | Trfhkmg | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xygjrdw | Bxnxnxb | $118.7 Bil | |||
| Moderna Inc
MRNA
| Hdvhgvm | Swhwd | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rxsflzts | Rmnysk | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Zbgtqnkx | Xpnb | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Hwxnhntk | Tktn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Rtkbqfzkx | Twhyq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Txzrnlmc | Bfj | $15.0 Bil | |||
| Incyte Corp
INCY
| Cbxqsmbh | Rljkwj | $13.5 Bil |